Caladrius Biosciences Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more
Caladrius Biosciences Inc. (0HS8) - Total Assets
Latest total assets as of September 2021: $102.54 Million USD
Based on the latest financial reports, Caladrius Biosciences Inc. (0HS8) holds total assets worth $102.54 Million USD as of September 2021.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Caladrius Biosciences Inc. - Total Assets Trend (2016–2020)
This chart illustrates how Caladrius Biosciences Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Caladrius Biosciences Inc. - Asset Composition Analysis
Current Asset Composition (December 2020)
Caladrius Biosciences Inc.'s total assets of $102.54 Million consist of 98.1% current assets and 1.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $631.00K | 1.8% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2020)
This chart illustrates how Caladrius Biosciences Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Caladrius Biosciences Inc.'s current assets represent 98.1% of total assets in 2020, an increase from 46.1% in 2016.
- Cash Position: Cash and equivalents constituted 45.9% of total assets in 2020, up from 13.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 1.8% of total assets.
Caladrius Biosciences Inc. Competitors by Total Assets
Key competitors of Caladrius Biosciences Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Caladrius Biosciences Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Caladrius Biosciences Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Caladrius Biosciences Inc. is currently not profitable relative to its asset base.
Caladrius Biosciences Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.15 | 12.09 | 10.52 |
| Quick Ratio | 11.15 | 12.09 | 10.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $52.10 Million | $ 70.90 Million | $ 33.15 Million |
Caladrius Biosciences Inc. - Advanced Valuation Insights
This section examines the relationship between Caladrius Biosciences Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.99 |
| Asset Growth Rate (YoY) | 32.6% |
| Total Assets | $36.00 Million |
| Market Capitalization | $35.60 Million USD |
Valuation Analysis
Near Book Valuation: The market values Caladrius Biosciences Inc.'s assets close to their book value ( 0.99x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Caladrius Biosciences Inc.'s assets grew by 32.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Caladrius Biosciences Inc. (2016–2020)
The table below shows the annual total assets of Caladrius Biosciences Inc. from 2016 to 2020.
| Year | Total Assets | Change |
|---|---|---|
| 2020-12-31 | $36.00 Million | +32.59% |
| 2019-12-31 | $27.15 Million | -39.09% |
| 2018-12-31 | $44.58 Million | -29.66% |
| 2017-12-31 | $63.38 Million | +18.43% |
| 2016-12-31 | $53.51 Million | -- |